Budget Impact Analysis of Drugs for Ultra-Rare Non-Oncological Diseases In Europe
نویسندگان
چکیده
منابع مشابه
Budget Impact Analysis of Drugs for Ultra-Rare Non-Oncological Diseases In Europe.
1Institute for Innovation & Valuation in Health Care (INNOVALHC), www.innoval-hc.com, An der Ringkirche 4, D-65197 Wiesbaden (Germany); 2University of Heidelberg (Germany), Mannheim Medical Faculty, Department of Public Health, Social and Preventive Medicine; 3University of Applied Economic Sciences Ludwigshafen (Germany); 4University of Marburg (Germany), Department of General Practice; 5Frank...
متن کاملBudget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
BACKGROUND/AIM Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. METHODS For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer's perspective, based on prevalence data for UODs for which patented drugs are available and...
متن کاملInvolvement of patient organisations in research and development of orphan drugs for rare diseases in europe.
Patients' representatives have an increasingly present voice in all aspects of drug development from fundamental research through regulatory processes to health technology assessment. Although major advances have been made in raising awareness and increasing funding for rare diseases, important challenges remain in terms of best use of resources, coordinating efforts and improving policy. This ...
متن کاملCharacteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR
BACKGROUND It has been suggested that ultra-rare diseases should be recognized as distinct from more prevalent rare diseases, but how drugs developed to treat ultra-rare diseases (DURDs) might be distinguished from drugs for 'other' rare diseases (DORDs) is not clear. We compared the characteristics of DURDs to DORDs from a health technology assessment (HTA) perspective in submissions made to t...
متن کاملNegotiating prices of drugs for rare diseases
Negotiating prices of drugs for rare diseases Séverine Henrard & Francis Arickx a Institute of Health and Society (IRSS), Université catholique de Louvain, Clos Chapelle-aux-Champs, 30 B1.30.15, 1200 Brussels, Belgium. b National Institute for Health and Disability Insurance (RIZIV/INAMI), Brussels, Belgium. Correspondence to Séverine Henrard (email: [email protected]). (Submitted: ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.08.1652